ST
Strides Pharma Science Ltd (STAR)
₹1,068.80
Mkt cap
₹9,851 Cr
P/E ratio
17.10
P/B
2.88
Div yield
0.47%
ROE
20.00%
ROCE
18.30%
EPS (TTM)
₹62.50
Book value
₹371
52W range
769–1,261
Sector
Healthcare
Price history
Previous close
Strides Pharma Science Ltd is in the business of development and manufacturing of pharmaceutical products. [1] The company's pharmaceutical products are sold in over 100 countries. [2] The company has always followed an inorganic growth strategy over the years that resulted in foray into new markets, addition of new business segments, therapy segments and manufacturing infrastructure. [3]
NSE STARBSE 532531
Health check
Constructive
ValuationCheap
ProfitabilityStrong
GrowthModerate
TechnicalsNeutral
52-week range
−15.24% from high₹1,069
₹769+39.05% from low₹1,261
Current
₹1,068.80
Prev close
₹1,097.50
Day
−2.62%
Price performance
1D
−4.05%
1W
+3.76%
1M
−10.20%
3M
−1.85%
6M
−0.04%
1Y
+28.97%
YTD
+18.66%
Financials
Revenue, profit & margin
P/E ratio
17.1×
STAR is 50% below the sector median of 34.4×
STAR17.1×
Sector median34.4×
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 999 | 1,006 | 1,044 | 1,054 | 1,167 | 1,154 | 1,190 | 1,120 | 1,221 | 1,195 | 1,323 | 1,265 | 1,430 | |
| Expenses | 889 | 876 | 874 | 866 | 983 | 943 | 973 | 902 | 990 | 959 | 1,084 | 1,037 | 1,179 | |
| Operating Profit | 111 | 129 | 169 | 188 | 184 | 210 | 218 | 218 | 231 | 236 | 240 | 228 | 251 | |
| OPM % | 11% | 13% | 16% | 18% | 16% | 18% | 18% | 19% | 19% | 20% | 18% | 18% | 18% | |
| Other Income | -129 | 60 | -27 | 3,299 | 25 | 4 | -12 | 0 | 18 | 104 | 3 | 68 | 3 | |
| Interest | 79 | 70 | 71 | 73 | 74 | 52 | 50 | 47 | 46 | 43 | 42 | 41 | 47 | |
| Depreciation | 60 | 49 | 48 | 47 | 48 | 48 | 49 | 49 | 50 | 51 | 53 | 56 | 57 | |
| Profit before tax | -157 | 70 | 23 | 3,369 | 86 | 114 | 106 | 122 | 153 | 245 | 148 | 200 | 150 | |
| Tax % | -5% | 23% | 55% | 1% | 16% | 21% | 20% | 13% | 14% | 15% | 13% | 17% | 11% | |
| Net Profit | -149 | 54 | 10 | 3,350 | 72 | 90 | 86 | 106 | 132 | 208 | 129 | 165 | 134 | |
| EPS in Rs | -14.54 | 5.40 | 1.98 | 364.69 | 7.81 | 9.54 | 8.91 | 10.80 | 13.84 | 21.93 | 13.77 | 17.02 | 14.20 | |
| Raw PDF |
Earnings
Results dates & reactionsNo upcoming results date on calendar.
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
Avg earnings-day move +0.02% · closed higher next day 20 of last 48
| Q3FY24 | Q4FY24 | Q1FY25 | Q2FY25 | Q3FY25 | Q4FY25 | Q1FY26 | Q2FY26 | Q3FY26 | Q4FY26† | Q1FY27 | Q2FY27 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Broadcast | 30 Jan '24◦ | 22 May '24◦ | 29 Jul '24◦ | 24 Oct '24◦ | 30 Jan '25◦ | 22 May '25◦ | 29 Jul '25 | 31 Oct '25 | 30 Jan '26 | 18 May '26◦ | 31 Jul '26 | 29 Oct '26◦ |
| Earnings day | −0.09% | −3.02% | +3.37% | −1.71% | +4.08% | +0.18% | +3.49% | +9.66% | +8.31% | −0.20% | +0.34% | −4.05% |
| +1 day | −0.92% | −4.57% | +3.79% | −2.11% | +2.69% | −3.40% | +2.49% | +15.53% | +3.31% | −0.01% | −2.97% | — |
| +5 days | +1.33% | −7.00% | +3.42% | +1.67% | +10.71% | +11.06% | −10.90% | +9.01% | +6.69% | +2.98% | −2.54% | — |
| +15 days | +18.69% | +4.69% | +28.81% | −9.31% | −3.30% | +20.83% | −4.91% | +4.33% | +7.40% | −11.85% | −3.06% | — |
| +30 days | +13.03% | +4.10% | +31.02% | +9.54% | −10.69% | +21.21% | −1.23% | +1.92% | +10.15% | −5.17% | +12.25% | — |
| Filing | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL |
Corporate actions
Last 6 months| Kind | Value | Ex-date | Record |
|---|---|---|---|
| dividend Dividend - Rs 5 Per Share | 5.00 | 31 Jul '26 | 31 Jul '26 |
Shareholding
as of Sep 202629.00%Promoter
Promoters29.00%1.09
FIIs27.98%0.42
DIIs15.51%0.09
Public27.52%0.76
Government0.01%
Ownership trend
Peers
8 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| Sun Pharma.Inds. | ₹1,777.70 | 34.66 | 4,26,530 | 0.90% | 1,995 | −10.53% | 16,199 | +11.88% | 20.53% |
| Divi's Lab. | ₹9,780.00 | 87.14 | 2,59,628 | 0.31% | 902 | +65.50% | 3,080 | +27.80% | 21.97% |
| Torrent Pharma. | ₹4,613.40 | 80.83 | 1,75,479 | 0.82% | 534 | −10.03% | 4,979 | +50.79% | 15.19% |
| Laurus Labs | ₹2,405.50 | 97.00 | 1,29,972 | 0.08% | 436 | +126.43% | 2,206 | +33.44% | 17.76% |
| Zydus Lifesci. | ₹1,245.50 | 25.52 | 1,24,239 | 0.08% | 990 | −35.09% | 8,017 | +21.96% | 21.14% |
| Dr Reddy's Labs | ₹1,352.00 | 40.30 | 1,12,849 | 0.59% | 913 | −31.35% | 8,698 | −1.48% | 13.04% |
| Cipla | ₹1,378.90 | 35.87 | 1,11,397 | 0.94% | 852 | −35.05% | 7,404 | −2.44% | 15.49% |
| Strides Pharma | ₹1,068.80 | 17.08 | 9,851 | 0.47% | 134 | −1.86% | 1,430 | +17.11% | 18.32% |
| Median: 158 Co. | ₹426.38 | 34.39 | 1,921 | 0.08% | 14 | +22.08% | 175 | +18.92% | 15.12% |
Filings
Annual reports15
Concall transcripts66
PPTOct 2026RECOct 2026TranscriptAug 2026PPTAug 2026RECAug 2026TranscriptMay 2026PPTMay 2026RECMay 2026TranscriptFeb 2026PPTFeb 2026TranscriptNov 2025PPTNov 2025TranscriptAug 2025PPTAug 2025RECAug 2025TranscriptMay 2025PPTMay 2025TranscriptFeb 2025PPTFeb 2025RECFeb 2025TranscriptOct 2024TranscriptOct 2024PPTOct 2024TranscriptAug 2024
Credit ratings6
Announcements5
Announcement under Regulation 30 (LODR)-Newspaper Publication 30 Oct - Newspaper Advertisement - Unaudited Financial Results for the quarter and half year ended September 30, 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome 30 Oct - Audio recording of earnings call for Q2 and H1 FY2026 results available on website.Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS 29 Oct - Allotment of Equity shares pursuant to exercise of Stock Options.Announcement under Regulation 30 (LODR)-Change in Directorate 29 Oct - Board appointed Biren Gabhawala as Non-Executive Independent Director from November 1, 2026 for five years.Announcement under Regulation 30 (LODR)-Investor Presentation 29 Oct - Earnings presentation for the quarter and half year ended September 30, 2026.